Garenoxacin shows promise for community-acquired pneumonia
An experimental fluoroquinole compared favorably with amoxicillin or ceftriaxone for treating community-acquired pneumonia in two phase III trials, researchers reported in poster presentations at the annual Inter-science Conference on Antimicrobial Agents and Chemotherapy. One study of 308 outpatients in
The company is developing garenoxacin and the lead investigator in the study was of
Bacterial eradication was achieved in 88% of the garenoxacin group and 91% of the amoxicillin group. Drug-related adverse events — most commonly diarrhea, headache, abdominal pain, and nausea — were seen in 13% of patients in the garenoxacin group and 12% of those in the amoxicillin group.
The second study of 406 hospitalized patients with CAP showed an 88% clinical cure rate in 328 evaluable patients regardless of treatment group. Patients were randomized to either IV garenoxacin 400 mg/day with possible step-down to oral carithromycin 500 mg b.i.d. If atypical pneumonia was suspected, the ceftriaxone patients also could receive IV erythromycin 0.5-1 g every 6 hours. Patients were treated for 7-14 days and evaluated for cure 7-14 days after completing therapy.
- Latest
- Trending